Further expanding the scope, a one-drug-multi-target approach was applied to repurpose existing drugs for dual cancer indications, revealing that levosimendan, a phosphodiesterase (PDE) inhibitor effective against HF, also exhibits activity against multiple cancers, including lymphoma, through the direct inhibition of RIOK1 and other kinases [59]. This evidence concerns the gene RIOK1 and cancer.